Tag: Bucillamine

January 30, 2018

Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of...
January 4, 2018

Revive Therapeutics Announces Update on its Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis…

Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel...
November 21, 2017

Revive Therapeutics Appoints Blockchain Expert, Bernie Doyle, as Technical Advisor to Support Development of Medical Cannabis Patient-Focused Program Enabled by Blockchain and AI Technology

Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel...
May 25, 2017

Revive Therapeutics Releases Financial Report

Revive Therapeutics announced the results for the three and nine months ended March 31, 2017.
March 29, 2017

Revive Therapeutics Gives Corporate Update

Revive Therapeutics (TSXV:RVV, OTCQB:RVVTF) updated the status of its clinical study for REV-004 Bucillamine in cystinuria and warrant exercise.